PHILADELPHIA (June 21, 2021)—Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently appointed medical oncology editor for the journal European Urology.
“It’s great to be able to bring multidisciplinary research to the forefront through this journal, which has a strong impact factor, a streamlined process for rapidly reviewing papers, and has been a reliable forum for publishing practice-changing findings,” said Plimack.
European Urology is the official journal of the European Association of Urology and seeks to improve the care of individuals with urological diseases, according to its mission statement. The monthly publication is read by more than 20,000 urologists worldwide and has been recognized as a prestigious journal for 35 years. Before becoming the medical oncology editor, Plimack submitted work to European Urology for several years and has worked with them as a reviewer.
“European Urology has skyrocketed to prominence in the urology, radiation oncology, and medical oncology fields. While it’s a urology journal, it’s really expanded into all those areas,” she said.
Plimack directs genitourinary clinical research at Fox Chase. The research looks at identifying biomarkers in neoadjuvant cisplatin-based chemotherapy in bladder cancer, as well as developmental therapeutics and immunotherapy in genitourinary malignancies. She specializes in the treatment of kidney, bladder, and prostate cancer, and runs a clinical practice focused on these diseases.
In addition to her other roles, Plimack is an elected member of the Board of Directors of the American Society of Clinical Oncology and an advisor to the Society of Urologic Oncology Clinical Trials Consortium. She was recently appointed chair of the scientific advisory board for the Bladder Cancer Advocacy Network and serves on multiple clinical trial steering and safety monitoring committees.
Plimack is also a member of the National Comprehensive Cancer Network guidelines panels for prostate, kidney, and bladder/penile cancers. She was also recently recognized as a 2021 Top Doctor by Philadelphia magazine.
“The field of research in patient care is international. I’m especially proud to be part of this effort bringing expertise from around the world to bear on issues important to the treatment of these cancers,” said Plimack.